SARS-CoV-2 Nucleocapsid (N) Protein


Prices from £249 (100μg ) –  For larger quantities, please contact us.


Product name: SARS-CoV-2 N-protein (Antigen)

Product description: Recombinant SARS-CoV-2 N-protein (Nucleoprotein, His-Tag) produced in Nicotiana benthamiana by Agrobacterium-mediated transient expression.



Expression host species: Nicotiana benthamiana

Host strain: Wuhan-Hu-1 (UniProtKB – P0DTC9 (NCAP_SARS2)) 1

Molecular weight: 46.5 kDa

Tag: C-terminal 6His

Uses: For research use only. Examples include SDS-PAGE, Western Blot, functional assays.

Relevance: The SARS-CoV-2 viral nucleocapsid protein serves multiple critical functions during the viral life cycle2. It binds and packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) structure and has a core role in virion assembly through its interactions with the membrane protein (M) and the viral genome. Due to its role in packaging the viral genome it also plays an essential role in viral replication3.



Purity: >90 % as shown by SDS-PAGE (Figure 1).

Biological activity: N/A

Endotoxin: Not tested.

Concentration: 1.59 mg/ml prior to lyophilization (analyzed by A280 measurement)

Aliquot size: 1 x 100 µg per tube



Formulation: Lyophilized from 20 mM HEPES, 300 mM NaCl, pH 7.5, 175 mM Trehalose Dihydrate.

Shipping: Recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.

Stability & Storage: See COA for detailed storage instructions. Lyophilized materials are stable for up to twelve months from date of receipt at -70℃.

It is recommended that reconstituted protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

Reconstitution: A hardcopy of COA with reconstitution instructions is included with the product.

SARS-CoV-2 Nucleocapsid (N) Protein

Figure 1: reducing 4-20% SDS-PAGE analysis of 2.5 µg SARS-CoV-2 N-protein.
Protein runs as a monomer.

Protein Sequence



  2. Kang S, Yang M, Hong Z, et al. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites [published online ahead of print, 2020 Apr 20]. Acta Pharm Sin B. 2020;10.1016/j.apsb.2020.04.009.
  3. Ye Q, West AMV, Silletti S, Corbett KD. Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein. bioRxiv [Preprint]. 2020 May 17:2020.05.17.100685. doi: 10.1101/2020.05.17.100685.

Contact us for more information.